What Foghorn Therapeutics Inc. does.

Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation.

The chromatin regulatory system orchestrates gene expression — the turning on and off of genes — which is fundamental to how all our cells function. The chromatin regulatory system is implicated in approximately 50 percent of all cancers, and understanding how this system works could lead to an entirely new class of precision medicines. To our knowledge, we are the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way.

Our proprietary Gene Traffic Control ® platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within this system. We have developed unique capabilities that have yielded new insights and scalability in drugging this new, previously untapped and promising area.

Revenue and profit, by fiscal year.

More on FHTX.

• Foghorn Therapeutics Inc. summary
• Foghorn Therapeutics Inc. financial statements
• Foghorn Therapeutics Inc. key metrics
• Foghorn Therapeutics Inc. health scores and style box
• Foghorn Therapeutics Inc. earnings
• Foghorn Therapeutics Inc. dividends
• Foghorn Therapeutics Inc. valuation
• Foghorn Therapeutics Inc. ownership and insiders
• Foghorn Therapeutics Inc. peers

Figures from Foghorn Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.